Immuno-Biological Laboratories Co., Ltd. (TYO:4570)

TYO:4570 Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	907	989	825	734	614	508
Cash & Short-Term Investments	907	989	825	734	614	508
Cash Growth	0.44%	19.88%	12.40%	19.54%	20.87%	-15.89%
Receivables	218	178	231	190	217	173
Inventory	415	379	317	321	318	326
Other Current Assets	19	23	17	17	16	122
Total Current Assets	1,559	1,569	1,390	1,262	1,165	1,129
Property, Plant & Equipment	210	213	191	135	119	120
Long-Term Investments	316	226	150	151	149	455
Other Intangible Assets	1	1	1	2	-	-
Long-Term Deferred Tax Assets	138	145	112	67	-	-
Other Long-Term Assets	2	1	1	1	1	1
Total Assets	2,226	2,155	1,845	1,618	1,434	1,705

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	6	2	3	4	5	3
Accrued Expenses	22	34	33	31	25	17
Short-Term Debt	144	142	140	135	130	125
Current Portion of Long-Term Debt	10	16	29	16	5	4
Current Income Taxes Payable	1	4	5	5	25	24
Other Current Liabilities	118	78	71	66	62	55
Total Current Liabilities	301	276	281	257	252	228
Long-Term Debt	17	18	35	84	99	104
Pension & Post-Retirement Benefits	15	13	10	7	4	3
Other Long-Term Liabilities	6	5	5	5	1	2
Total Liabilities	339	312	331	353	356	337

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	50	50	50	50	3,029	3,029
Additional Paid-In Capital	1,040	1,040	1,040	1,040	2,061	2,061
Retained Earnings	799	754	425	176	-4,009	-3,720
Treasury Stock	-1	-1	-1	-1	-1	-1
Comprehensive Income & Other	-1	-	-	-	-2	-1
Shareholders' Equity	1,887	1,843	1,514	1,265	1,078	1,368
Total Liabilities & Equity	2,226	2,155	1,845	1,618	1,434	1,705

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	171	176	204	235	234	233
Net Cash (Debt)	736	813	621	499	380	275
Net Cash Growth	4.10%	30.92%	24.45%	31.32%	38.18%	-46.50%
Net Cash Per Share	79.03	87.29	66.68	53.58	40.80	29.53
Filing Date Shares Outstanding	9.31	9.31	9.31	9.31	9.31	9.31
Total Common Shares Outstanding	9.31	9.31	9.31	9.31	9.31	9.31
Working Capital	1,258	1,293	1,109	1,005	913	901
Book Value Per Share	202.61	197.89	162.56	135.82	115.75	146.88
Tangible Book Value	1,886	1,842	1,513	1,263	1,078	1,368
Tangible Book Value Per Share	202.50	197.78	162.45	135.61	115.75	146.88

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 23, 2026

Data Sources Report a data error